Trial Profile
Raltegravir + nevirapine to avoid renal dysfunction and fractures in patients with HIV-1 infections.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Nov 2015
Price :
$35
*
At a glance
- Drugs Nevirapine (Primary) ; Raltegravir (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 19 Nov 2015 New trial record
- 25 Sep 2015 Results published in the Antiviral Therapy